Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 16/20 | 0.83 |
| ▸ | PDE4B | Q07343 | 16/20 | 0.83 |
| ▸ | PDE4A | P27815 | 14/20 | 0.83 |
| ▸ | PDE4C | Q08493 | 14/20 | 0.83 |
| ▸ | PDE7A | Q13946 | 2/20 | 0.83 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.83 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.83 |
| ▸ | PDE7B | Q9NP56 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5556838 | 1.00 | PDE4D (0.83) | PDE4DPDE4BPDE4APDE4CPDE7A | |
| SCHEMBL6307463 | 0.91 | PDE4D (1.00) | PDE4DPDE4BPDE4APDE4CPDE7A | |
| SCHEMBL5564177 | 0.91 | PDE4D (1.00) | PDE4DPDE4BPDE4APDE4CPDE7A | |
| SCHEMBL5564171 | 0.91 | PDE4D (1.00) | PDE4DPDE4BPDE4APDE4CPDE7A | |
| SCHEMBL6307457 | 0.91 | PDE4D (1.00) | PDE4DPDE4BPDE4APDE4CPDE7A | |
| SCHEMBL5564179 | 0.91 | PDE4D (1.00) | PDE4DPDE4BPDE4APDE4CPDE7A | |
| SCHEMBL5564048 | 0.90 | PDE4B (1.00) | PDE4DPDE4BPDE4APDE4CPDE7A | |
| SCHEMBL6871258 | 0.90 | PDE4B (1.00) | PDE4DPDE4BPDE4APDE4CPDE7A | |
| SCHEMBL5564051 | 0.90 | PDE4B (1.00) | PDE4DPDE4BPDE4APDE4CPDE7A | |
| SCHEMBL5558463 | 0.88 | PDE4D (0.83) | PDE4DPDE4BPDE4APDE4CPDE7A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150119399-A1 | BETA-CELL REPLICATION PROMOTING COMPOUNDS AND METHODS OF THEIR USE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2015-04-30 | — | — | US | claimed |
| EP-2804603-A1 | BETA-CELL REPLICATION PROMOTING COMPOUNDS AND METHODS OF THEIR USE | President and Fellows of Harvard College (US) | 2014-11-26 | — | — | EP | claimed |
| WO-2013106547-A1 | BETA-CELL REPLICATION PROMOTING COMPOUNDS AND METHODS OF THEIR USE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2013-07-18 | — | — | WO | claimed |
| EP-1587512-A2 | PDE4 INHIBITORS FOR THE TREATMENT OF NEOPLASMS OF LYMPHOID CELLS | ALTANA Pharma AG (DE) | 2005-10-26 | — | — | EP | claimed |
| US-20050112069-A1 | Pharmaceutical composition of a pde4 or pde 3/4 inhibitor and histamine receptor antagonist | NYCOMED GMBH (DE) | 2005-05-26 | — | — | US | claimed |
| US-6846821-B2 | Tetrahydrothiopy ranphthalazinone derivatives as PDE4 inhibitors | ALTANA PHARMA, AG (DE) | 2005-01-25 | — | — | US | claimed |
| WO-2004062671-A2 | PDE4 INHIBITORS FOR THE TREATMENT OF NEOPLASMS OF LYMPHOID CELLS | ALTANA PHARMA AG (DE) | 2004-07-29 | — | — | WO | claimed |
| US-20150119399-A1 | BETA-CELL REPLICATION PROMOTING COMPOUNDS AND METHODS OF THEIR USE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2015-04-30 | — | — | US | disclosed |
| EP-2804603-A1 | BETA-CELL REPLICATION PROMOTING COMPOUNDS AND METHODS OF THEIR USE | President and Fellows of Harvard College (US) | 2014-11-26 | — | — | EP | disclosed |
| WO-2013106547-A1 | BETA-CELL REPLICATION PROMOTING COMPOUNDS AND METHODS OF THEIR USE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2013-07-18 | — | — | WO | disclosed |
| EP-1849468-A2 | Pharmaceutical composition of a pde4 or a pde3/4 inhibitor and a histamine receptor antagonist | Nycomed GmbH (DE) | 2007-10-31 | — | — | EP | disclosed |
| US-20060148804-A1 | Pde4 inhibitors for the treatment of neoplasms of lymphoid cells | NYCOMED GMBH (DE) | 2006-07-06 | — | — | US | disclosed |
| EP-1587512-A2 | PDE4 INHIBITORS FOR THE TREATMENT OF NEOPLASMS OF LYMPHOID CELLS | ALTANA Pharma AG (DE) | 2005-10-26 | — | — | EP | disclosed |
| EP-1482938-A1 | PHARMACEUTICAL COMPOSITION OF A PDE4 OR A PDE3/4 INHIBITOR AND A HISTAMINE RECEPTOR ANTAGONIST | ALTANA Pharma AG (DE) | 2004-12-08 | — | — | EP | disclosed |
| WO-2004062671-A2 | PDE4 INHIBITORS FOR THE TREATMENT OF NEOPLASMS OF LYMPHOID CELLS | ALTANA PHARMA AG (DE) | 2004-07-29 | — | — | WO | disclosed |
| WO-2003074055-A1 | PHARMACEUTICAL COMPOSITION OF A PDE4 OR A PDE3/4 INHIBITOR AND A HISTAMINE RECEPTOR ANTAGONIST | ALTANA PHARMA AG (DE) | 2003-09-12 | — | — | WO | disclosed |
| US-20030166655-A1 | Tetrahydrothiopy ranphthalazinone derivatives as PDE4 inhibitors | ALTANA PHARMA AG (DE) | 2003-09-04 | — | — | US | disclosed |
| US-6544993-B1 | Tetrahydrothiopyranphthalazinone derivatives as PDE4 inhibitors | ALTANA PHARMA AG (DE) | 2003-04-08 | — | — | US | disclosed |
| EP-1244654-A1 | TETRAHYDROTHIOPY RANPHTHALAZINONE DERIVATIVES AS PDE4 INHIBITORS | ALTANA Pharma AG (DE) | 2002-10-02 | — | — | EP | disclosed |
| WO-2001030777-A1 | TETRAHYDROTHIOPY RANPHTHALAZINONE DERIVATIVES AS PDE4 INHIBITORS | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 2001-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060148804-A1 | Pde4 inhibitors for the treatment of neoplasms of lymphoid cells | PDE4A, PDE4B, PDE4C | PDE4D 4/4885PDE4B 2/4885PDE4A 1/4885 |
| US-20150119399-A1 | BETA-CELL REPLICATION PROMOTING COMPOUNDS AND METHODS OF THEIR USE | IAPP, GPR119, PCNA | PDE4D 1307/4885PDE4B 1204/4885PDE4A 1173/4885 |
| US-20030166655-A1 | Tetrahydrothiopy ranphthalazinone derivatives as PDE4 inhibitors | PDE4A, PDE4B, PDE3A | PDE4D 8/4885PDE4B 2/4885PDE4A 1/4885 |
| US-20050112069-A1 | Pharmaceutical composition of a pde4 or pde 3/4 inhibitor and histamine receptor antagonist | HRH4, PDE4A, PDE4B | PDE4D 9/4885PDE4B 3/4885PDE4A 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.